| # | Title | Journal | Year | Citations |
|---|
| 1 | International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma | Lancet Oncology, The | 2014 | 3,343 |
| 2 | Multiple Myeloma | New England Journal of Medicine | 2011 | 2,109 |
| 3 | International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma | Lancet Oncology, The | 2016 | 1,866 |
| 4 | Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma | New England Journal of Medicine | 2015 | 948 |
| 5 | Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma | Leukemia | 2008 | 787 |
| 6 | Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma | New England Journal of Medicine | 2012 | 692 |
| 7 | Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report | Blood | 2015 | 586 |
| 8 | MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis | Proceedings of the National Academy of Sciences of the United States of America | 2008 | 507 |
| 9 | IMWG consensus on risk stratification in multiple myeloma | Leukemia | 2014 | 500 |
| 10 | Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial | Journal of Clinical Oncology | 2010 | 400 |
| 11 | Efficacy and safety of once-weekly bortezomib in multiple myeloma patients | Blood | 2010 | 361 |
| 12 | Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study | Lancet Haematology,the | 2016 | 344 |
| 13 | Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† | Annals of Oncology | 2021 | 316 |
| 14 | Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN) | Blood | 2011 | 309 |
| 15 | Thalidomide for treatment of multiple myeloma: 10 years later | Blood | 2008 | 294 |
| 16 | Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group | Leukemia | 2013 | 294 |
| 17 | European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications | Haematologica | 2015 | 289 |
| 18 | Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial | Lancet Oncology, The | 2015 | 289 |
| 19 | International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation | Blood | 2011 | 282 |
| 20 | Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide | Blood | 2012 | 260 |
| 21 | Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data | Lancet Oncology, The | 2014 | 256 |
| 22 | Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients | Blood | 2011 | 247 |
| 23 | Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study | Lancet Haematology,the | 2020 | 244 |
| 24 | Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study | Lancet Oncology, The | 2013 | 219 |
| 25 | Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM | Blood | 2016 | 207 |
| 26 | The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network | Annals of Oncology | 2009 | 201 |
| 27 | Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial | Lancet Haematology,the | 2020 | 201 |
| 28 | Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials | Haematologica | 2013 | 193 |
| 29 | European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma | Haematologica | 2014 | 185 |
| 30 | Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma | Blood | 2016 | 179 |
| 31 | IMWG consensus on maintenance therapy in multiple myeloma | Blood | 2012 | 178 |
| 32 | Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial | Lancet Haematology,the | 2019 | 174 |
| 33 | Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2013 | 168 |
| 34 | Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study | Leukemia | 2008 | 163 |
| 35 | International Myeloma Working Group recommendations for global myeloma care | Leukemia | 2014 | 162 |
| 36 | Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial | Lancet Oncology, The | 2021 | 162 |
| 37 | Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma | Frontiers in Oncology | 2020 | 156 |
| 38 | Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia | Blood | 2015 | 151 |
| 39 | MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts | Blood | 2007 | 144 |
| 40 | Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi | Annals of Oncology | 2014 | 133 |
| 41 | 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease | Leukemia | 2016 | 120 |
| 42 | Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better? | Leukemia | 2020 | 117 |
| 43 | Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma | Journal of Molecular Diagnostics | 2015 | 115 |
| 44 | Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project | Journal of Clinical Oncology | 2022 | 115 |
| 45 | Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma | Blood | 2011 | 113 |
| 46 | From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives | Haematologica | 2018 | 110 |
| 47 | Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN) | Leukemia | 2020 | 109 |
| 48 | Thromboelastogram monitoring in the perioperative period of hepatectomy for adult living liver donation | Liver Transplantation | 2004 | 108 |
| 49 | Early versus delayed autologous transplantation after immunomodulatory agents‐based induction therapy in patients with newly diagnosed multiple myeloma | Cancer | 2012 | 106 |
| 50 | Chlorambucil plus rituximab with or without maintenance rituximab as first‐line treatment for elderly chronic lymphocytic leukemia patients | American Journal of Hematology | 2014 | 104 |
